Fosaprepitant
فوسآپریپیتانت
🍽️ Alimentary Tract And MetabolismNK1 receptor antagonist (IV)
Market / country: 🇺🇸 USA
Emend IV (US)
🧮 Dose calculator
Chemotherapy-induced nausea and vomiting · Regimen source: FDA Fosaprepitant · 2.1
- • Finish about 30 min before chemotherapy; with dexamethasone and a 5-HT3 antagonist. Children 6 months–17 y (≥6 kg) per Tables 3 and 4. FDA Fosaprepitant · 2.1FDA Fosaprepitant · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to any component; concomitant pimozide (QT prolongation). FDA Fosaprepitant · 4
Warnings
- • Clinically significant CYP3A4 interactions; decreased INR with warfarin (monitor days 7–10); reduced hormonal contraceptive efficacy for 28 days. FDA Fosaprepitant · 5
- • Hypersensitivity reactions; infusion-site reactions. FDA Fosaprepitant · 5
Formulations
- 150 mg vial — powder for injection 🇺🇸 USA FDA Fosaprepitant · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fosaprepitant · 8.1
“Risk Summary There are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Fosaprepitant · 8.2
“Risk Summary Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fosaprepitant · 8.4
“The safety and effectiveness of a single dose and a 3-day regimen of fosaprepitant have been established in pediatric patients 6 months to 17 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC and MEC.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fosaprepitant · 8.5
“In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ].”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Fosaprepitant · 8.3
“Contraception Upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced.”
🔗 Reference links
- FDA (approval record)ANDA210625
- DailyMed (FDA label)FDA Fosaprepitant
- MedlinePlus (NIH)Aprepitant/Fosaprepitant Injection
- WHO ATC/DDD❌ None
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Fosaprepitant · 3FDA Fosaprepitant · 2.1FDA Fosaprepitant · 2.2FDA Fosaprepitant · 4FDA Fosaprepitant · 5FDA Fosaprepitant · SPL approval / marketing categoryFDA Fosaprepitant · 8.1FDA Fosaprepitant · 8.2FDA Fosaprepitant · 8.4FDA Fosaprepitant · 8.5FDA Fosaprepitant · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified